Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 4.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 478,864 shares of the company's stock after selling 23,993 shares during the quarter. Principal Financial Group Inc. owned about 0.96% of Immunocore worth $14,208,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of IMCR. GF Fund Management CO. LTD. purchased a new stake in Immunocore in the fourth quarter valued at approximately $25,000. Oppenheimer Asset Management Inc. purchased a new stake in Immunocore during the first quarter worth approximately $225,000. NEOS Investment Management LLC grew its stake in Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after buying an additional 1,102 shares during the period. Tema Etfs LLC purchased a new stake in Immunocore during the fourth quarter worth approximately $330,000. Finally, Virtus ETF Advisers LLC grew its stake in Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock worth $340,000 after buying an additional 3,238 shares during the period. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Immunocore from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research note on Monday, June 2nd. Needham & Company LLC reiterated a "buy" rating and set a $71.00 price objective on shares of Immunocore in a research note on Thursday, April 10th. Oppenheimer boosted their price objective on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research report on Monday, April 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $58.89.

Immunocore Stock Up 1.7%

IMCR traded up $0.59 during trading on Wednesday, hitting $35.74. The company had a trading volume of 157,445 shares, compared to its average volume of 342,786. The company has a market cap of $1.80 billion, a PE ratio of -83.11 and a beta of 0.77. The business has a 50-day moving average of $32.95 and a 200-day moving average of $30.67. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.36 and a quick ratio of 6.31. Immunocore Holdings PLC Sponsored ADR has a 1-year low of $23.15 and a 1-year high of $41.54.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.45. The firm had revenue of $125.13 million for the quarter, compared to analysts' expectations of $108.82 million. Immunocore had a negative net margin of 6.48% and a negative return on equity of 5.86%. The firm's quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.49) earnings per share. As a group, analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.